Depatux-M and temozolomide in advanced high-grade glioma

Neurooncol Adv. 2020 Jun 6;2(1):vdaa063. doi: 10.1093/noajnl/vdaa063. eCollection 2020 Jan-Dec.

Sophie Hirsch^{1

2

3

4}, Cristiana Roggia⁵, Saskia Biskup⁶, Benjamin Bender⁷, Irina Gepfner-Tuma^{1

2

3}, Franziska Eckert^{3

8}, Daniel Zips^{3

8}, Nisar P Malek^{4

9}, Helmut Wilhelm¹⁰, Mirjam Renovanz¹¹, Ghazaleh Tabatabai^{1

2

3}

¹ Department of Neurology and Interdisciplinary Neuro-Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
² Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany.
³ Center for Neuro-Oncology, Comprehensive Cancer Center Tübingen-Stuttgart, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁴ Center for Personalized Medicine, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁵ Department of Genetics, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁶ CeGaT and Praxis for Human Genetics, Tübingen, Germany.
⁷ Department of Diagnostic and Interventional Neuroradiology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁸ Department of Radiation Oncology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
⁹ Department of Internal Medicine I, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
¹⁰ Department of Ophtalmology, Division of Neuro-ophtalmology, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.
¹¹ Department of Neurosurgery, University Hospital Tübingen, Eberhard Karls University Tübingen, Tübingen, Germany.

No abstract available